Remove 2005 Remove Compounding Remove Immunization
article thumbnail

GLP-1s Effective as Adjunctive Therapy in Patients with T1D, Obesity | ADA 2025

Drug Topics

image credit: photoopus / stock.adobe.com The first GLP-1RA approved for use in the US was exenatide (Byetta) in 2005 for patients with type 2 diabetes (T2D). The abstract provides evidence of GLP-1RAs and their ability to interact with other necessary agents in diabetes care.

article thumbnail

FDA Approves Nitisinone for Treatment of Alkaptonuria

Drug Topics

Patients were enrolled at the National Institutes of Health Clinical Center between April 2005 and March 2006, with 20 people receiving no treatment and 20 receiving nitisinone once daily. All patients were aged 18 to 65 years of age, except for 1 who was older than 65 years.

FDA 341
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Diabetes Risk Reduction Practices Low for Women With Gestational Diabetes

Drug Topics

They included patients from a large regional hospital in northern Victoria, Australia, who attended the diabetes center from July 2004 to July 2005 for the management of gestational diabetes. The pilot study was aimed at determining diabetes risk reduction behavior when achieving a healthy weight and being physically active.

article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful. 3 Moreover, some studies have suggested that co-administration of these compounds can modulate the effects of one another at a receptor level.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

With alpha particles, you must be very careful how the drug is made to ensure that the compound remains stable between manufacturing and use. Following his graduate studies, Dr Hoppin was an Alexander von Humboldt Fellow at the Research Center Jülich, Center for Electronics in Germany from 2003 to 2005.

article thumbnail

Conference Coverage Recap: American Pharmacists Association Annual Meeting and Exposition 2025

Drug Topics

Wildfires Have Significant Impacts on Respiratory Health Laura Stiles June 9th 2025 Article There were more fires in the span of a 13-year period from 2005 to 2018 than in the previous 2 decades. McKesson ideaShare: Wrapping Up The Week June 25th 2023 Podcast Drug Topics wraps up a great week in Las Vegas at McKesson ideaShare.

article thumbnail

Hashimoto’s and Graves’ Remission after Helicobacter Pylori Eradication

The Thyroid Pharmacist

8) In very simple terms, this theory hypothesizes that our immune system begins to attack our own thyroid gland because we are infected with a pathogenic organism (like a bacterium, parasite , or virus ), that looks similar to components of the thyroid gland. Molecular mimicry is one of the leading theories of autoimmune disease. (8)